Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 108

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 108
---
 execute these growth strategies, including our additional laboratory in Mexico, or manage our anticipated growth effectively, our business could be harmed. Our success depends on the continued emergence and growth of markets for analysis of genetic variation and the ability to generate substantial demand for our tests. The usefulness of our technologies is dependent on the availability of genetic data and its applications in clinical, research, and consumer settings. We are focusing on markets for analysis of genomic variations and omics profiling, using technologies such as sequencing, genotyping, gene expression profiling, deep phenotyping and artificial intelligence. However, these markets are relatively new and emerging, and may not develop as quickly as anticipated. In addition, changes in the regulatory environment and budgetary pressures could reduce research and development budgets and government funding, adversely affecting our business. We depend on sequencing technology, and the 28 introduction of next -generationsequencing technologies has reduced the cost of sequencing and accordingly the accessibility of this service and has therefore increased demand for sequencing -relatedproducts and services. However, in the event that the cost of sequencing increases or does not decrease at a fast enough rate, our business, results of operations, financial condition and growth prospects will be adversely affected. As with all new market categories, a major challenge is to make consumers and clinicians aware of the benefits of our tests and services, including the price, the breadth of our testing options, and the benefits of having additional genetic data available from which to make preventive and treatment decisions. A lack of or delay in clinical acceptance of broad -basedpanels such as our tests would negatively impact sales and market acceptance of our tests and limit our revenue growth and potential profitability. If we are not able to generate demand for our tests at sufficient volume, or if it takes significantly more time to generate this demand than we anticipate, our business, prospects, financial condition and results of operations could be materially harmed. In addition, our success depends on demand for our products. Our customers may experience volatility in their genetic testing demand in the ordinary course of their operations. Since our tests are often purchased on a test -by -testbasis rather than pursuant to long -termpurchasing arrangements, our consumer base may fluctuate or decrease. In addition, the long -termdistribution agreements that we do have may be terminated, which could affect demand as well. The loss of any of our customers, or a reduction in orders or difficulties collecting payments for tests, could significantly reduce our revenue and adversely affect our business, results of operations, financial condition and growth prospects. We may be forced